Format

Send to

Choose Destination
See comment in PubMed Commons below
Urol Clin North Am. 2012 Nov;39(4):547-60. doi: 10.1016/j.ucl.2012.07.010.

Targeting angiogenesis as a promising modality for the treatment of prostate cancer.

Author information

1
Department of Medical Oncology, Jefferson Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA. Jianqing.lin@jefferson.edu

Abstract

Antiangiogenic therapy has been successful for the treatment of solid tumors. Several strategies have been used to target angiogenesis in prostate cancer. These strategies include blocking proangiogenic factors via monoclonal antibodies or small molecule inhibitors targeting downstream signaling effector pathways, or using agents with immune-modulatory effects. This review examines the general concepts of tumor angiogenesis and the key clinical trials that have used these agents and other novel biologics in prostate cancer. Targeting angiogenesis is still a promising treatment strategy in prostate cancer with a rational trial design and combination approach.

PMID:
23084530
DOI:
10.1016/j.ucl.2012.07.010
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center